ARWR

41.3705.22%
JC

James C. Hamilton

Chief Medical Officer and Head of R&D

Dr. James C. Hamilton, M.D., MBA was the Chief of Discovery and Translational Medicine at Arrowhead Pharmaceuticals, Inc since December 2022 until 2025, is Chief Medical Officer and Head of R&D since 2025 and was its Senior Vice President of Discovery and Translational Medicine until December 2022. He is Strategic Advisor at Linden Lake Venture Capital. He served as a Head of Clinical Development and Vice President of Arrowhead Pharmaceuticals, Inc. Dr. Hamilton served as President of Calando Pharmaceuticals, Inc. (Calando). Dr. Hamilton served as Vice President of Medical Technologies of Arrowhead Pharmaceuticals, Inc. since May 2008. He is a licensed medical practitioner. In 2005, he co-founded NanoValent Pharmaceuticals, a nanoparticle vaccine delivery firm. Dr. Hamilton served as a Biotechnology Analyst at Reservoir Ventures, where he helped delineate a product strategy for several portfolio biotech and medical device companies. He consulted for biotechnology venture funds. Dr. Hamilton led the clinical development of ARO-HBV (now JNJ-3989), which was licensed to Janssen Pharmaceuticals. In parallel, Dr. Hamilton served as Head of Corporate Development and led Arrowhead in-licensing transaction of Novartis’ RNAi assets, as well as the out-licensing of ARO-LPA (now AMG890) to Amgen and the ARO-AAT partnership with Takeda. He graduated Magna cum Laude from Miami University and holds an MD degree from The Ohio State University, with Post-graduate specialty training in Emergency Medicine. Dr. Hamilton also completed an MBA at the Fisher College of Business at The Ohio State University.

公司職務